Oxford BioMedica plc Stock London S.E.
Equities
GB0006648157_GB
GB0006648157
Biotechnology & Medical Research
Sales 2024 * | 129M 166M | Sales 2025 * | 165M 211M | Capitalization | 348M 445M |
---|---|---|---|---|---|
Net income 2024 * | -36M -46.11M | Net income 2025 * | -12M -15.37M | EV / Sales 2024 * | 2.55 x |
Net cash position 2024 * | 18.3M 23.44M | Net cash position 2025 * | 14.94M 19.13M | EV / Sales 2025 * | 2.02 x |
P/E ratio 2024 * |
-9.04
x | P/E ratio 2025 * |
-23.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.57% |
Latest transcript on Oxford BioMedica plc
Managers | Title | Age | Since |
---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 23-03-26 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 17-08-28 |
Chairman | 68 | 20-06-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 23-04-30 |
Chairman | 68 | 20-06-23 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 16-05-31 |
1st Jan change | Capi. | |
---|---|---|
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |